As Hong Kong's 18A biopharmaceutical sector approaches a period of 'value reassessment' in 2026, a profound paradigm shift centered on 'industrialized biomanufacturing' and a 'revolution in drug delivery scenarios' is quietly underway. Over the past decade, China's pharmaceutical innovation has often focused on intense competition in crowded fields like monoclonal antibodies and ADCs, relying on heavy investment, talent acquisition, and rapid clinical progress to drive valuations. However, as homogenized competition increases pressure from national drug price negotiations and raises the bar for going global, the market is beginning to recognize that a true competitive moat involves more than just discovering a new target. Within this grand industry narrative, BAO PHARMA-B (02659) is charting a different course. Leveraging its unique synthetic biology foundation and 'scenario-driven' strategy, the company is evolving from a traditional biotech firm into a critical 'connector' for the upgrade of China's biopharmaceutical industry.
From a broad industry perspective, the next phase of biopharmaceuticals is essentially a race centered on 'manufacturing as R&D.' The core logic of BAO PHARMA-B lies in its deep understanding of biomanufacturing industrialization. It is understood that by utilizing a commercial-scale production platform covering the three major host systems—CHO cells, Pichia pastoris, and E. coli—the company is achieving a form of technological substitution akin to a 'dimensional advantage.' Taking recombinant human chymotrypsin (KJ101) and recombinant ulinastatin (BJ044) as examples, these are not simple imitations. Instead, they use advanced genetic engineering techniques to completely supersede the era of traditional biochemical drugs, which for decades relied on animal organ extraction, faced unstable raw material supply, and carried viral risks. This green manufacturing capability, based on synthetic biology, not only aligns with national calls to tackle critical 'bottleneck' technologies but also secures a strategic position of 'total cost leadership' for the company in an era of healthcare cost containment. For BAO PHARMA-B, industrial capability is no longer merely a late-stage support function but a competitive advantage determined from the molecular design phase.
This 'infrastructural' logic is most evident in the approval of the company's core product – injectable human hyaluronidase (Baoshuyi®, KJ017). Currently, the global biologics market is at a historic inflection point, transitioning from intravenous infusion to high-volume subcutaneous delivery. Intravenous infusion not only consumes significant medical resources but also limits the potential for at-home patient treatment. The emergence of KJ017 essentially builds a 'high-speed road' for the Chinese biologics market to access the subcutaneous delivery scenario. This classic 'pick-and-shovel' business model means its value is not limited by its own sales volume but is deeply tied to the entire multi-billion dollar biologics market's shift away from intravenous administration. As industry leaders join BAO PHARMA-B's subcutaneous delivery ecosystem, the company is effectively reshaping the value ceiling for 18A enterprises by controlling the 'access rights' to new delivery scenarios.
Simultaneously, BAO PHARMA-B is presenting the market with a textbook example of how an 18A company can achieve self-sufficiency through its 'pyramid-shaped' pipeline strategy. At the base of the pyramid are products like SJ02 (recombinant human long-acting follicle-stimulating hormone), which boast high clinical certainty and address clear market needs. Against a backdrop of societal concerns over fertility rates and surging demand for assisted reproductive technologies, SJ02 transforms the ordeal of daily injections into a weekly regimen. Through a strong channel partnership, this product is rapidly becoming a stable cash flow pillar for the company. At the apex of the pyramid, disruptive therapies with first-in-class potential, such as KJ103 (recombinant IgG-degrading enzyme), demonstrate rapid efficacy in treating severe autoimmune diseases. This dual-engine model of 'stable cash flow + high-value innovation' allows BAO PHARMA-B to exhibit remarkable strategic resilience amidst capital market fluctuations.
Currently, BAO PHARMA-B has established nearly 100,000 square meters of production facilities and 26,000 liters of reactor capacity. With over 70% of its personnel dedicated to R&D, this significant investment is not a signal of short-term profit-taking but a clear indication that management's interests are aligned with the long-term value of these scarce 'industrial assets.' As the industry navigates cyclical challenges, BAO PHARMA-B has transcended being a company that merely bets on clinical data. It is now contributing 'standards' and 'infrastructure' to China's biopharmaceutical industrialization, deeply embedding itself into the gears of the entire industry's upgrade. For a company so deeply invested in foundational technologies and focused on clinical scenarios, the long-term logic of its role as a 'foundational operator' in Chinese biopharma is gradually gaining momentum.
Comments